Immune checkpoint inhibitor integration in locoregionally advanced nasopharyngeal carcinoma: a prospective evidence synthesis on efficacy, safety, and therapeutic optimization
Peng Chen, Ying Jiang, Chen Han, Lian Jian, Yu Gong, Hui Xie, Ziying Zhang, Yaqian Han · 2026
Read Immune checkpoint inhibitor integration in locoregionally advanced nasopharyngeal carcinoma: a prospective evidence synthesis on efficacy, safety, and therapeutic optimization by Peng Chen, Ying Jiang, Chen Han, Lian Jian, Yu Gong, Hui Xie, Ziying Zhang, Yaqian Han (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13350252.txt.
Description
Peng Chen and colleagues pooled trial evidence in 2026 on immune checkpoint drugs for advanced nasopharyngeal cancer. This tumour of the upper throat is common in parts of Asia. Seven prospective trials with 1,788 patients were combined.
Regimens with these drugs produced high survival estimates. Three-year overall survival reached 96.4 percent. Failure-free survival reached 88.2 percent in the pooled data. Comparisons across strategies probed timing and chemotherapy partners. They also weighed treatment length and which drug was used. The main question has shifted. It is no longer whether these drugs work, but how best to weave them into combined therapy. The synthesis maps those choices.
Catalog record
| CREATOR | Peng Chen, Ying Jiang, Chen Han, Lian Jian, Yu Gong, Hui Xie, Ziying Zhang, Yaqian Han |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54482 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |